These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39101128)

  • 1. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.
    Bidlingmaier C; Heller C; Langer F; Miesbach W; Scholz U; Oldenburg J; Nüesch E; Palmborg H; Santagostino E; Tiede A
    Res Pract Thromb Haemost; 2024 Jul; 8(5):102482. PubMed ID: 39101128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
    Álvarez-Román MT; Shapiro AD; Ragni MV; Palmborg H; Bystrická L; Szamosi J; Casiano S; Chambost H
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102163. PubMed ID: 37720484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.
    Chowdary P; Holmström M; Mahlangu JN; Ozelo MC; Pabinger I; Pasi KJ; Ragni MV; Shapiro A; Barnowski C; Lethagen S
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12760. PubMed ID: 35910942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
    Shrestha A; Su J; Li N; Barnowski C; Jain N; Everson K; Jena AB; Batt K
    Res Pract Thromb Haemost; 2021 Jan; 5(1):94-103. PubMed ID: 33537533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
    Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
    Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
    Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
    Konkle BA; Oldenburg J; Pasi J; Kulkarni R; Nolan B; Mahlangu J; Young G; Brown SA; Pabinger I; Shapiro A; Négrier C; Blanchette V; Ragni MV; Dumont J; Lethagen S
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102180. PubMed ID: 37753224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
    Lagassé HAD; Ou J; Sauna ZE; Golding B
    Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eftrenonacog Alfa: A Review in Haemophilia B.
    Lamb YN; Hoy SM
    Drugs; 2023 Jun; 83(9):807-818. PubMed ID: 37081241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
    Funding E; Lowe G; Poulsen LH; Shapiro S; Oldenburg J; Eriksson D; Falk A; Rich C
    Adv Ther; 2023 Sep; 40(9):3770-3783. PubMed ID: 37351812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
    Nolan B; Klukowska A; Shapiro A; Rauch A; Recht M; Ragni M; Curtin J; Gunawardena S; Mukhopadhyay S; Jayawardene D; Winding B; Fischer K; Liesner R
    Blood Adv; 2021 Jul; 5(13):2732-2739. PubMed ID: 34242387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.